Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 5, Issue 3, 2013, Pages

  Donovan, Laura E ^a   Dammer, Eric B ^a   Duong, Duc M ^a   Hanfelt, John J ^a   Levey, Allan I ^a   Seyfried, Nicholas T ^a   Lah, James J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

alpha granule secretion; amyloidogenic protein; blood biomarkers; coagulation; glycoprotein; mass spectrometry; matrix metalloprotease inhibitor; membrane proteomics; platelet activation

Indexed keywords

BIOLOGICAL MARKER; FIBRONECTIN; MEMBRANE PROTEIN; PEPTIDE; PROTEOME; THROMBOSPONDIN 1; VON WILLEBRAND FACTOR; APOLIPOPROTEIN E; BETA 2 MICROGLOBULIN; CD45 ANTIGEN; CHYLOMICRON; FIBRINOGEN; FIBRINOGEN RECEPTOR; GELATINASE A; GELATINASE B; GELSOLIN; GLYCOPROTEIN; GLYCOPROTEIN IB; GLYCOPROTEIN V; PROTEIN; SECRETORY GRANULE PROTEIN; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTION; FLOW CYTOMETRY; FRACTIONATION; GEL; HUMAN; MOLECULAR WEIGHT; NORMAL DISTRIBUTION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEOMICS; REVERSED PHASE LIQUID CHROMATOGRAPHY; SECRETORY GRANULE; TANDEM MASS SPECTROMETRY; THROMBOCYTE MEMBRANE; ULTRACENTRIFUGATION; CELL ISOLATION; COMPARATIVE STUDY; HISTOGRAM; HUMAN CELL; IMMUNOBLOTTING; MINI MENTAL STATE EXAMINATION; QUANTITATIVE ANALYSIS; RNA EDITING; SIGNAL NOISE RATIO; SILVER STAINING; THROMBOCYTE ACTIVATION; THROMBOCYTE RELEASE REACTION;

EID: 84882245417     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt186     Document Type: Article

References (108)

1. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K, Proceedings of the National Academy of Sciences of the United States of America 1985 82 4245 4249 10.1073/pnas.82.12.4245 3159021 (Pubitemid 15053619)
2. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Glenner GG, Wong CW, Biochemical and Biophysical Research Communications 1984 120 885 890 10.1016/S0006-291X(84)80190-4 6375662 (Pubitemid 14104991)
3. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Lee V, Balin B, Otvos L, Trojanowski J, Science 1991 251 675 678 10.1126/science.1899488 1899488 (Pubitemid 21916893)
4. Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis. Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai L-H, The Journal of Neuroscience 2010 30 14946 14954 10.1523/JNEUROSCI.4305-10.2010 21068297
5. Rho Kinase II Phosphorylation of the Lipoprotein Receptor LR11/SORLA Alters Amyloid-β Production. Herskowitz JH, Seyfried NT, Gearing M, Kahn RA, Peng J, Levey AI, Lah JJ, Journal of Biological Chemistry 2011 286 6117 6127 10.1074/jbc.M110.167239 21147781
6. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L, The Lancet Neurology 2006 5 228 234 10.1016/S1474-4422(06)70355-6 (Pubitemid 43238346)
7. CSF markers for incipient Alzheimer's disease. Blennow K, Hampel H, The Lancet Neurology 2003 2 605 613 10.1016/S1474-4422(03)00530-1 (Pubitemid 37162569)
8. Platelet activation: assessment and quantification. Kamath S, Blann AD, Lip GYH, European Heart Journal 2001 22 1561 1571 10.1053/euhj.2000.2515 11492985 (Pubitemid 32801301)
9. Current methods of assessing platelet function: relevance to transfusion medicine. Cardigan R, Turner C, Harrison P, Vox Sanguinis 2005 88 153 163 10.1111/j.1423-0410.2005.00618.x 15787725 (Pubitemid 40516261)
10. Proteomic and Phospho-Proteomic Profile of Human Platelets in Basal, Resting State: Insights into Integrin Signaling. Qureshi AH, Chaoji V, Maiguel D, Faridi MH, Barth CJ, Salem SM, Singhal M, Stoub D, Krastins B, Ogihara M, Zaki MJ, Gupta V, PLoS One 2009 4 7627 10.1371/journal.pone.0007627 19859549
11. Platelets in inflammation and atherogenesis. Gawaz M, Langer H, May AE, The Journal of Clinical Investigation 2005 115 3378 3384 10.1172/JCI27196 16322783 (Pubitemid 43121822)
12. Investigating GABA and its function in platelets as compared to neurons. Kaneez FS, Saeed SA, Platelets 2009 20 328 333 10.1080/09537100903047752 19637096
13. The metabolism of serotonin in neuronal cells in culture and platelets. Fatima Shad K, Saeed S, Experimental Brain Research 2007 183 411 416 10.1007/s00221-007-1133-7
14. Serotonylation of Small GTPases Is a Signal Transduction Pathway that Triggers Platelet ±-Granule Release. Walther DJ, Peter J-U, Winter S, Höltje M, Paulmann N, Grohmann M, Vowinckel J, Alamo-Bethencourt V, Wilhelm CS, Ahnert-Hilger G, Bader M, Cell 2003 115 851 862 10.1016/S0092-8674(03) 01014-6 14697203 (Pubitemid 38058497)
15. The amyloid precursor protein of Alzheimer's disease is released by human platelets. Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, Currie J, Ames D, Weidemann A, Fischer P, Journal of Biological Chemistry 1990 265 15977 15983 2118534
16. Low-density platelet populations demonstrate low in vivo activity in sporadic Alzheimer disease. JAREMO P, MILOVANOVIC M, BULLER C, NILSSON S, WINBLAD B, Platelets 2012 23 116 120 10.3109/09537104.2011.593654 22150375
17. Platelet amyloid precursor protein isoform expression in Alzheimer's disease: evidence for peripheral marker. Vignini A, Sartini D, Morganti S, Nanetti L, Luzzi S, Provinciali L, Mazzanti L, Emanuelli M, Int J Immunopathol Pharmacol 2011 24 529 534 21658330
18. Platelet amyloid precursor protein processing: A bio-marker for Alzheimer's disease. Tang K, Hynan LS, Baskin F, Rosenberg RN, Journal of the neurological sciences 2006 240 53 58 10.1016/j.jns.2005.09.002 16256140 (Pubitemid 41814953)
19. Predictive value of platelet activation for the rate of cognitive decline in Alzheimer/'s disease patients. Stellos K, Panagiota V, Kogel A, Leyhe T, Gawaz M, Laske C, J Cereb Blood Flow Metab 2010 30 1817 1820 10.1038/jcbfm.2010.140 20717123
20. Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease. Prodan CI, Ross ED, Stoner JA, Cowan LD, Vincent AS, Dale GL, Neurology 2011 76 247 252 10.1212/WNL.0b013e3182074bd2 21242492
21. Determinants of platelet activation in Alzheimer's disease. Ciabattoni G, Porreca E, Di Febbo C, Di Iorio A, Paganelli R, Bucciarelli T, Pescara L, Del Re L, Giusti C, Falco A, Sau A, Patrono C, Davì G, Neurobiology of Aging 2007 28 336 342 10.1016/j.neurobiolaging.2005.12.011 16442186 (Pubitemid 46177381)
22. Association of platelet-derived soluble glycoprotein VI in plasma with Alzheimer's disease. Laske C, Leyhe T, Stransky E, Eschweiler GW, Bueltmann A, Langer H, Stellos K, Gawaz M, Journal of Psychiatric Research 2008 42 746 751 10.1016/j.jpsychires.2007.07.017 17854831 (Pubitemid 351636099)
23. Platelet Activation in Alzheimer's Disease: From Pathophysiology to Clinical Value. Laske C, Sopova K, Stellos K, Curr Vasc Pharmacol 2012
24. Association of Platelet Activation with Vascular Cognitive Impairment: Implications in Dementia Development? Stellos K, Katsiki N, Tatsidou P, Bigalke B, Laske C, Curr Vasc Pharmacol 2012
25. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Thambisetty M, Lovestone S, Biomark Med 2010 4 65 79 10.2217/bmm.09.84 20387303
26. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Rifai N, Gillette MA, Carr SA, Nat Biotech 2006 24 971 983 10.1038/nbt1235 (Pubitemid 44215392)
27. Platelet mRNA: the meaning behind the message. Rowley JW, Schwertz H, Weyrich AS, Current opinion in hematology 2012 19 385 391 10.1097/MOH. 0b013e328357010e 22814651
28. Alteration of the platelet transcriptome in chronic kidney disease. Plé H, Maltais M, Corduan A, Rousseau G, Madore F, Provost P, Thrombosis and haemostasis 2012 108 605 10.1160/TH12-03-0153 22836280
29. Platelet membrane proteomics: a novel repository for functional research. Lewandrowski U, Wortelkamp S, Lohrig K, Zahedi RP, Wolters DA, Walter U, Sickmann A, Blood 2009 114 10 e19 10.1182/blood-2009-02-203828 19436052
30. The Human Platelet Membrane Proteome Reveals Several New Potential Membrane Proteins. Moebius J, Zahedi RP, Lewandrowski U, Berger C, Walter U, Sickmann A, Molecular & Cellular Proteomics 2005 4 1754 1761 10.1074/mcp.M500209-MCP200 23875185 (Pubitemid 41749268)
31. Comparison of Label-free Methods for Quantifying Human Proteins by Shotgun Proteomics. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR, Resing KA, Ahn NG, Molecular & Cellular Proteomics 2005 4 1487 1502 10.1074/mcp.M500084-MCP200 23875185 (Pubitemid 41555475)
32. Purine Nucleotides Induce Regulated Secretion of von Willebrand Factor: Involvement of Cytosolic Ca2+ and Cyclic Adenosine Monophosphate-Dependent Signaling in Endothelial Exocytosis. Vischer UM, Wollheim CB, Blood 1998 91 118 127 9414275 (Pubitemid 28018735)
33. Up-regulation of NG2 proteoglycan and interferon-induced transmembrane proteins 1 and 3 in mouse astrocytoma: a membrane proteomics approach. Seyfried NT, Huysentruyt LC, Atwood JA, Xia Q, Seyfried TN, Orlando R, Cancer Lett 2008 263 243 252 10.1016/j.canlet.2008.01.007 18281150
34. Analysis of a membrane-enriched proteome from postmortem human brain tissue in Alzheimer's disease. Donovan LE, Higginbotham L, Dammer EB, Gearing M, Rees HD, Xia Q, Duong DM, Seyfried NT, Lah JJ, Levey AI, PROTEOMICS-Clinical Applications 2012 6 201 211 10.1002/prca.201100068 22532456
35. Systematical optimization of reverse-phase chromatography for shotgun proteomics. Xu P, Duong DM, Peng J, J Proteome Res 2009 8 3944 3950 10.1021/pr900251d 19566079
36. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. Peng J, Elias JE, Thoreen CC, Licklider LJ, Gygi SP, J Proteome Res 2003 2 43 50 10.1021/pr025556v 12643542 (Pubitemid 36207189)
37. Systematic approach for validating the ubiquitinated proteome. Seyfried NT, Xu P, Duong DM, Cheng D, Hanfelt J, Peng J, Anal Chem 2008 80 4161 4169 10.1021/ac702516a 18433149 (Pubitemid 351812770)
38. Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimers disease. Gozal YM, Duong DM, Gearing M, Cheng D, Hanfelt J, Funderburk C, Peng J, Lah J, Levey A, Journal of Proteome Research 2009
39. Clinical proteomics in neurodegenerative diseases. Zhou J-Y, Hanfelt J, Peng J, PROTEOMICS-Clinical Applications 2007 1 1342 1350 10.1002/prca.200700378 21136634
40. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Huang DW, Sherman BT, Lempicki RA, Nat Protocols 2008 4 44 57 10.1038/nprot.2008.211
41. Recent advances in platelet structural physiology. White JG, Gerrard JM, Supplementum ad Thrombosis and haemostasis 1978 63 49 60 262546
42. Predicting transmembrane protein topology with a hidden markov model: application to complete genomes. Krogh A, Larsson B, von Heijne G, Sonnhammer ELL, J Mol Biol 2001 305 567 580 10.1006/jmbi.2000.4315 11152613 (Pubitemid 33032862)
43. Neuroproteomics: expression profiling of the brain's proteomes in health and disease. Kim SI, Voshol H, van Oostrum J, Hastings TG, Cascio M, Glucksman MJ, Neurochem Res 2004 29 1317 1331 15176488 (Pubitemid 39023504)
44. Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease. Thambisetty M, Simmons A, Hye A, Campbell J, Westman E, Zhang Y, Wahlund L-O, Kinsey A, Causevic M, Killick R, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Spenger C, Lovestone S, the AddNeuroMed consortium, PLoS One 2011 6 28527 10.1371/journal.pone.0028527 22205954
45. Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM, PLoS One 2011 6 18850 10.1371/journal.pone.0018850 21526197
46. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. Ryu JK, McLarnon JG, Journal of Cellular and Molecular Medicine 2009 13 2911 2925 10.1111/j.1582-4934.2008. 00434.x 18657226
47. Activation of Human Platelets by Misfolded Proteins. Herczenik E, Bouma B, Korporaal SJA, Strangi R, Zeng Q, Gros P, Van Eck M, Van Berkel TJC, Gebbink MFBG, Akkerman J-WN, Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 1657 1665 10.1161/ATVBAHA.107.143479 17510465 (Pubitemid 46986124)
48. Fibrinogen and §ssup§2§esup§-Amyloid Association Alters Thrombosis and Fibrinolysis: A Possible Contributing Factor to Alzheimer's Disease. Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D, Bhuvanendran S, Fenz KM, Strickland S, Neuron 2010 66 695 709 10.1016/j.neuron.2010.05.014 20547128
49. Alpha-granule membrane mirrors the platelet plasma membrane and contains the glycoproteins Ib, IX, and V. Berger G, Masse J, Cramer E, Blood 1996 87 1385 1395 8608228 (Pubitemid 26056902)
50. Interaction of Platelet Glycoprotein V with Glycoprotein Ib-IX Regulates Expression of the Glycoproteins and Binding of von Willebrand Factor to Glycoprotein Ib-IX in Transfected Cells. Meyer SC, Fox JEB, Journal of Biological Chemistry 1995 270 14693 14699 10.1074/jbc.270.24.14693 7782333
51. Glycoprotein Ib forms disulfide bonds with 2 glycoprotein Ibβ subunits in the resting platelet. Luo S-Z, Mo X, Afshar-Kharghan V, Srinivasan S, López JA, Li R, Blood 2007 109 603 609 10.1182/blood-2006-05-024091 17008541 (Pubitemid 46105958)
52. Von Willebrand factor promoter targets the expression of amyloid β protein precursor to brain vascular endothelial cells of transgenic mice. Jahroudi N, Schmaier A, Srikanth S, Mahdi F, Lutka FA, Bowser R, Journal of Alzheimer's Disease 2003 5 149 158 23874297 (Pubitemid 36582773)
53. Thrombospondins Are Astrocyte-Secreted Proteins that Promote CNS Synaptogenesis. Christopherson KS, Ullian EM, Stokes CCA, Mullowney CE, Hell JW, Agah A, Lawler J, Mosher DF, Bornstein P, Barres BA, Cell 2005 120 421 433 10.1016/j.cell.2004.12.020 15707899 (Pubitemid 40222435)
54. Thrombospondin-1 induces platelet activation through CD36-dependent inhibition of the cAMP/protein kinase A signaling cascade. Roberts W, Magwenzi S, Aburima A, Naseem KM, Blood 2010 116 4297 4306 10.1182/blood-2010-01-265561 20664056
55. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Isenberg JS, Wink DA, Roberts DD, Cardiovascular Research 2006 71 785 793 10.1016/j.cardiores.2006.05.024 16820142 (Pubitemid 44848003)
56. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Isenberg JS, Romeo MJ, Yu C, Yu CK, Nghiem K, Monsale J, Rick ME, Wink DA, Frazier WA, Roberts DD, Blood 2008 111 613 623 10.1182/blood-2007-06-098392 17890448
57. Immunohistochemical Identification of Thrombospondin in Normal Human Brain and in Alzheimer's Disease. Buee L, Hof PR, Roberts DD, Delacourte A, Morrison JH, Fillit HM, American Journal of Pathology 1992 141 783 788 1415477
58. Human neutrophil alpha-defensins induce formation of fibrinogen and thrombospondin-1 amyloid-like structures and activate platelets via glycoprotein IIb/IIIa. Horn M, Bertling A, Brodde MF, MÜLler A, Roth J, Van Aken H, Jurk K, Heilmann C, Peters G, Kehrel BE, Journal of Thrombosis and Haemostasis 2012 10 647 661 10.1111/j.1538-7836.2012.04640.x 22268819
59. Increased Binding of Beta-2-Microglobulin to Blood Cells in Dialysis Patients Treated with High-Flux Dialyzers Compared with Low-Flux Membranes Contributed to Reduced Beta-2-Microglobulin Concentrations. Traut M, Haufe CC, Eismann U, Deppisch RM, Stein G, Wolf G, Blood Purification 2007 25 432 440 10.1159/000110069 17957097 (Pubitemid 351194885)
60. CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, Chung KA, Millard SP, Nutt JG, Montine TJ, American Journal of Clinical Pathology 2008 129 526 529 10.1309/W01Y0B808EMEH12L 18343778 (Pubitemid 352029270)
61. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez J-C, Proteomics 2003 3 1486 1494 10.1002/pmic.200300470 12923774 (Pubitemid 37048074)
62. Binding of Gelsolin, a Secretory Protein, to Amyloid β-Protein. Chauhan VPS, Ray I, Chauhan A, Wisniewski HM, Biochemical and Biophysical Research Communications 1999 258 241 246 10.1006/bbrc.1999.0623 10329371 (Pubitemid 29287035)
63. Apolipoprotein E includes a binding site which is recognized by several amyloidogenic polypeptides. Baumann MH, Kallijärvi J, Lankinen H, Soto C, Haltia M, Biochemical Journal 2000 349 77 84 10.1042/0264-6021:3490077 10861213 (Pubitemid 30440167)
64. Plasma Gelsolin is Decreased and Correlates with Rate of Decline in Alzheimer's Disease. Güntert A, Campbell J, Saleem M, O'Brien DP, Thompson AJ, Byers HL, Ward MA, Lovestone S, Journal of Alzheimer's Disease 2010 21 585 596 23874297
65. Plasma gelsolin: function, prognostic value, and potential therapeutic use. Bucki R, Levental I, Kulakowska A, Janmey PA, Current Protein & Peptide Science 2008 9 541 551 10.2174/138920308786733912 23875183
66. MGAT3 mRNA: A Biomarker for Prognosis and Therapy of Alzheimer's Disease by Vitamin D and Curcuminoids. Fiala M, Mahanian M, Rosenthal M, Mizwicki MT, Tse E, Cho T, Sayre J, Weitzman R, Porter V, Journal of Alzheimer's Disease 2011 25 135 144 23874297
67. A large scale multivariate parallel ICA method reveals novel imaging-genetic relationships for Alzheimer's disease in the ADNI cohort. Meda SA, Narayanan B, Liu J, Perrone-Bizzozero NI, Stevens MC, Calhoun VD, Glahn DC, Shen L, Risacher SL, Saykin AJ, Pearlson GD, Neuroimage 2012 60 1608 1621 10.1016/j.neuroimage.2011.12.076 22245343
68. Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate- synthase by amyloid precursor protein processing and is affected in Alzheimer's disease. Grimm MOW, Kuchenbecker J, Rothhaar TL, Grösgen S, Hundsdörfer B, Burg VK, Friess P, Müller U, Grimm HS, Riemenschneider M, Hartmann T, Journal of Neurochemistry 2011 116 916 925 10.1111/j.1471-4159. 2010.07070.x 21214572
69. A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P, Journal of Neurochemistry 1995 65 717 724 7616228
70. The Role of IGF-1 Receptor and Insulin Receptor Signaling for the Pathogenesis of Alzheimer's Disease: From Model Organisms to Human Disease. Freude S, Schilbach K, Schubert M, Current Alzheimer Research 2009 6 213 223 10.2174/156720509788486527 19519303
71. Ca2+ dysfunction in neurodegenerative disorders: Alzheimer's disease. Fedrizzi L, Carafoli E, BioFactors 2011 37 189 196 10.1002/biof.157 21698698
72. Neuronal Calcium Signaling, Mitochondrial Dysfunction, and Alzheimer's Disease. Supnet C, Bezprozvanny I, Journal of Alzheimer's Disease 2010 20 487 498 23874297
73. Functional Links Between Aβ Toxicity, Endocytic Trafficking, and Alzheimer's Disease Risk Factors in Yeast. Treusch S, Hamamichi S, Goodman JL, Matlack KES, Chung CY, Baru V, Shulman JM, Parrado A, Bevis BJ, Valastyan JS, Han H, Lindhagen-Persson M, Reiman EM, Evans DA, Bennett DA, Olofsson A, DeJager PL, Tanzi RE, Caldwell KA, Caldwell GA, Lindquist S, Science 2011 334 1241 1245 10.1126/science.1213210 22033521
74. Molecular Motors in Neurons: Transport Mechanisms and Roles in Brain Function, Development, and Disease. Hirokawa N, Niwa S, Tanaka Y, Neuron 2010 68 610 638 10.1016/j.neuron.2010.09.039 21092854
75. A Role for Myosin VI in the Localization of Axonal Proteins. Lewis TL jr, Mao T, Arnold DB, PLoS Biol 2011 9 1001021 10.1371/journal.pbio.1001021 21390300
76. Isoprenoids, small GTPases and Alzheimer's disease. Hooff GP, Wood WG, Müller WE, Eckert GP, Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 2010 1801 896 905 10.1016/j.bbalip.2010.03.014
77. Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type. Söderberg M, Edlund C, Alafuzoff I, Kristensson K, Dallner G, Journal of Neurochemistry 1992 59 1646 1653 10.1111/j.1471-4159.1992.tb10994.x 1402910
78. Polyubiquitin Linkage Profiles in Three Models of Proteolytic Stress Suggest the Etiology of Alzheimer Disease. Dammer EB, Na CH, Xu P, Seyfried NT, Duong DM, Cheng D, Gearing M, Rees H, Lah JJ, Levey AI, Rush J, Peng J, Journal of Biological Chemistry 2011 286 10457 10465 10.1074/jbc.M110.149633 21278249
79. It May Take Inflammation, Phosphorylation and Ubiquitination to 'Tangle' in Alzheimer's Disease. Arnaud L, Robakis NK, Figueiredo-Pereira ME, Neurodegenerative Diseases 2006 3 313 319 10.1159/000095638 16954650 (Pubitemid 46034207)
80. Pathways by Which Aβ Facilitates Tau Pathology. Blurton-Jones M, LaFerla FM, Current Alzheimer Research 2006 3 437 448 10.2174/156720506779025242 17168643 (Pubitemid 46066423)
81. The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H, Alexander DB, Ide C, Horan TP, Arakawa T, Yoshida H, Nishikawa S-i, Itoh Y, Seiki M, Itohara S, Takahashi C, Noda M, Cell 2001 107 789 800 10.1016/S0092-8674(01)00597-9 11747814 (Pubitemid 34033671)
82. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, Kitaura Y, Takai S, Sasahara RM, Horimoto A, Ikawa Y, Ratzkin BJ, Arakawa T, Noda M, Proceedings of the National Academy of Sciences 1998 95 13221 13226 10.1073/pnas.95.22.13221 (Pubitemid 28509552)
83. RECK modulates Notch signaling during cortical neurogenesis by regulating ADAM10 activity. Muraguchi T, Takegami Y, Ohtsuka T, Kitajima S, Chandana EPS, Omura A, Miki T, Takahashi R, Matsumoto N, Ludwig A, Noda M, Takahashi C, Nat Neurosci 2007 10 838 845 10.1038/nn1922 17558399 (Pubitemid 47013438)
84. Metalloproteinases in biology and pathology of the nervous system. Yong VW, Power C, Forsyth P, Edwards DR, Nat Rev Neurosci 2001 2 502 511 10.1038/35081571 11433375 (Pubitemid 33676585)
85. Does a Pro-Inflammatory Process Precede Alzheimer's Disease and Mild Cognitive Impairment? Ferretti MT, Cuello AC, Current Alzheimer Research 2011 8 164 174 10.2174/156720511795255982 21345170
86. Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-β Peptide (1-40). Backstrom JR, Lim GP, Cullen MJ, Tökés ZA, The Journal of Neuroscience 1996 16 7910 7919 8987819 (Pubitemid 26405054)
87. Ibuprofen and lipoic acid codrug 1 control Alzheimer's disease progression by down-regulating protein kinase C ù-mediated metalloproteinase 2 and 9 levels in β-amyloid infused Alzheimer's disease rat model. Zara S, Rapino M, Sozio P, Di Stefano A, Nasuti C, Cataldi A, Brain Research 2011 1412 79 87 21820649
88. Investigation of Matrix Metalloproteinases, MMP-2 and MMP-9, in Plasma Reveals a Decrease of MMP-2 in Alzheimer's Disease. Lim NKH, Villemagne VL, Soon CPW, Laughton KM, Rowe CC, McLean CA, Masters CL, Evin G, Li Q-X, Journal of Alzheimer's Disease 2011 26 779 786 23874297
89. Thrombospondin Type 1 Repeats Interact with Matrix Metalloproteinase 2. Bein K, Simons M, Journal of Biological Chemistry 2000 275 32167 32173 10900205
90. Insulin promotes the biosynthesis and secretion of apolipoprotein B-48 by altering apolipoprotein B mRNA editing. Thorngate FE, Raghow R, Wilcox HG, Werner CS, Heimberg M, Elam MB, Proceedings of the National Academy of Sciences 1994 91 5392 5396 10.1073/pnas.91.12.5392 (Pubitemid 24174333)
91. Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. Farese RV, Véniant MM, Cham CM, Flynn LM, Pierotti V, Loring JF, Traber M, Ruland S, Stokowski RS, Huszar D, Young SG, Proceedings of the National Academy of Sciences 1996 93 6393 6398 10.1073/pnas.93.13.6393 (Pubitemid 26230316)
92. Apolipoprotein B mRNA editing and apolipoprotein gene expression in the liver of hyperinsulinemic fatty Zucker rats: relationship to very low density lipoprotein composition. Elam MB, von Wronski MA, Cagen L, Thorngate F, Kumar P, Heimberg M, Wilcox HG, Lipids 1999 34 809 816 10.1007/s11745-999-0427-z 10529091 (Pubitemid 29439830)
93. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL, The Journal of Clinical Investigation 1998 101 1084 1093 10.1172/JCI1847 9486979 (Pubitemid 28125287)
94. Hyperinsulinemia provokes synchronous increases in central inflammation and β-amyloid in normal adults. Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S, Arch Neurol 2005 62 1539 1544 10.1001/archneur.62.10.noc50112 16216936 (Pubitemid 41434558)
95. Association of Metabolic Dysregulation With Volumetric Brain Magnetic Resonance Imaging and Cognitive Markers of Subclinical Brain Aging in Middle-Aged Adults. Tan ZS, Beiser AS, Fox CS, Au R, Himali JJ, Debette S, DeCarli C, Vasan RS, Wolf PA, Seshadri S, Diabetes Care 2011 34 1766 1770 10.2337/dc11-0308 21680719
96. Binding of Thrombospondin to Human Plasma Lipoproteins. Muraishi A, Capuzzi DM, Tuszynski GP, Biochemical and Biophysical Research Communications 1993 193 1145 1151 10.1006/bbrc.1993.1745 8323538 (Pubitemid 23209714)
97. Chylomicron amyloid-beta in the aetiology of Alzheimer's disease. Takechi R, Galloway S, Pallebage-Gamarallage MMS, Mamo JCL, Atherosclerosis Supplements 2008 9 19 25 18640080
98. Effects of VLDL, chylomicrons, and chylomicron remnants on platelet aggregability. Orth M, Luley C, Wieland H, Thrombosis Research 1995 79 297 305 10.1016/0049-3848(95)00116-9 8533125
99. Chylomicron-induced prothrombin activation and platelet aggregation. Xu N, Ohlin AK, Nilsson A, Arteriosclerosis, Thrombosis, and Vascular Biology 1994 14 1014 1020 10.1161/01.ATV.14.6.1014
100. Platelets are the primary source of amyloid β-peptide in human blood. Chen M, Inestrosa NC, Ross GS, Fernandez HL, Biochemical and Biophysical Research Communications 1995 213 96 103 10.1006/bbrc.1995.2103 7639768
101. Protease nexin-II (amyloid beta-protein precursor): a platelet alpha-granule protein. van Nostrand WE, Schmaier AH, Farrow JS, Cunningham DD, Science 1990 248 745 748 10.1126/science.2110384 2110384
102. Low-density platelet populations demonstrate low in vivo activity in sporadic Alzheimer disease. Järemo P, Milovanovic M, Buller C, Nilsson S, Winblad B, Platelets 2012 23 116 120 10.3109/09537104.2011.593654 22150375
103. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Casserly I, Topol EJ, The Lancet 2004 363 1139 1146 10.1016/S0140-6736(04)15900-X (Pubitemid 38452789)
104. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K, Nat Med 2003 9 61 67 12483207 (Pubitemid 36098261)
105. Contribution of vascular risk factors to the progression in alzheimer disease. Helzner EP, Luchsinger JA, Scarmeas N, Consentino S, Brickman AM, Glymour MM, Stern Y, Archives of Neurology 2009 66 343 348 10.1001/archneur.66. 3.343 19273753
106. Rate of MMSE score change in Alzheimer's disease: Influence of education and vascular risk factors. Roselli F, Tartaglione B, Federico F, Lepore V, Defazio G, Livrea P, Clinical Neurology and Neurosurgery 2009 111 327 330 10.1016/j.clineuro.2008.10.006 19036496
107. Platelet protein shake as playmaker. van der Meijden PE, Heemskerk JW, Blood 2012 120 2931 2932 10.1182/blood-2012-08-450080 23065006
108. STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Snel B, Lehmann G, Bork P, Huynen MA, Nucleic Acids Research 2000 28 3442 3444 10.1093/nar/28.18.3442 10982861